Clinical

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data.

Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.

How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival.

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

With radiopharmaceutical therapy use up 20 times in Medicare, experts analyze clinical pathways for delivering it in academic and community settings.

Higher local recurrence growth rates and high-grade tumors were linked to increased disease-specific death after resection.

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus chemotherapy as a standard-of-care option based on improved pathologic response and event-free survival outcomes.

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic therapy focused on disease control and survival in advanced stages.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

Patients with myasthenia gravis (MG) had greater morbidity and extended hospitalization when they underwent cardiac surgery.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.